DLBCL is highly correlated with the abnormal activation of PI3K/Akt/mTOR pathways, and inhibiting the activity of PI3Kδ is beneficial for DLBCL patients [3,4]. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.